Meningococcal Polysaccharide AO-Acetylation Levels Do Not Impact the Immunogenicity of the Quadrivalent Meningococcal Tetanus Toxoid Conjugate Vaccine: Results from a Randomized, Controlled Phase III Study of Healthy Adults Aged 18 to 25 Years

The epidemiology of meningococcal disease in Latin America 1945–2010: an unpredictable and changing landscape

(2012) M. A. P. SÁFADI et al.   EPIDEMIOLOGY AND INFECTION

The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine

(2012) Ghassan Dbaibo et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Laboratory-Based Surveillance of Neisseria meningitidis Isolates from Disease Cases in Latin American and Caribbean Countries, SIREVA II 2006–2010

(2012) Ana Belén Ibarz-Pavón et al.   PLoS One

The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine

(2012) Ghassan Dbaibo et al.   Human Vaccines & Immunotherapeutics

Maintenance of Immune Response throughout Childhood following Serogroup C Meningococcal Conjugate Vaccination in Early Childhood

(2011) A. Khatami et al.   Clinical and Vaccine Immunology

Meningococcal disease in Asia: an under-recognized public health burden

(2011) A. VYSE et al.   EPIDEMIOLOGY AND INFECTION

Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults

(2011) Nancy Bermal et al.   Human vaccines & immunotherapeutics

Immunogenicity of a Single Dose of Tetravalent Meningococcal Serogroups A, C, W-135, and Y Conjugate Vaccine Administered to 2- to 10-year-olds Is Noninferior to a Licensed-ACWY Polysaccharide Vaccine With an Acceptable Safety Profile

(2011) Ziad A. Memish et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal ACWY Tetanus Toxoid Conjugate Vaccine in Healthy Adolescents and Young Adults 10 to 25 Years of Age

(2011) Roger Baxter et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix® in subjects aged 11–17 years: An open, randomised, controlled trial

(2011) Lars Østergaard et al.   VACCINE

Meningococcal conjugate vaccines: optimizing global impact

(2011) Andrew Terranella et al.   Infection and Drug Resistance

Meningococcal Quadrivalent (Serogroups A, C, W135, and Y) Conjugate Vaccine (Menveo®)

(2010) Emma D. Deeks   BIODRUGS

Epidemiological Profile of Meningococcal Disease in the United States

(2010) Lee H. Harrison   CLINICAL INFECTIOUS DISEASES

The epidemiology of meningococcal disease and the impact of vaccines

(2010) Ameneh Khatami et al.   Expert Review of Vaccines

Menveo®: a novel quadrivalent meningococcal CRM197conjugate vaccine against serogroups A, C, W-135 and Y

(2010) Brian Cooper et al.   Expert Review of Vaccines

Advances in the Development of Vaccines againstNeisseria meningitidis

(2010) Lionel K.K. Tan et al.   NEW ENGLAND JOURNAL OF MEDICINE

W135 Invasive Meningococcal Strains Spreading in South America: Significant Increase in Incidence Rate in Argentina

(2009) A. M. Efron et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Safety and Immunogenicity of a Tetravalent Polysaccharide Vaccine Against Meningococcal Disease

(2009) Pei-Lan Shao et al.   JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION

Meningococcal carriage and disease—Population biology and evolution

(2009) Dominique A. Caugant et al.   VACCINE

Global epidemiology of meningococcal disease

(2009) Lee H. Harrison et al.   VACCINE

A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children

(2009) M. Knuf et al.   VACCINE

Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2–10 years of age

(2009) S. Black et al.   VACCINE

Emergence of Endemic Serogroup W135 Meningococcal Disease Associated with a High Mortality Rate in South Africa

(2008) A. von Gottberg et al.   CLINICAL INFECTIOUS DISEASES

Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity

(2008) Martin C. J. Maiden et al.   JOURNAL OF INFECTIOUS DISEASES

Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15–25 years

(2008) Lars Østergaard et al.   VACCINE